Current Report Filing (8-k)
November 04 2022 - 9:16AM
Edgar (US Regulatory)
0001638287
false
--12-31
0001638287
2022-11-03
2022-11-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2022
NeuroBo
Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
|
001-37809 |
|
47-2389984 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
200 Berkeley Street, 19th Floor
Boston, Massachusetts 02116
(Address of principal executive offices, including Zip
Code) |
Registrant’s
Telephone Number, Including Area Code: (857) 702-9600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.001 per share |
|
NRBO |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.03 |
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On November 3, 2022,
the board of directors of NeuroBo Pharmaceuticals, Inc. (the “Company”) approved an amendment (the “Bylaws
Amendment”) to the Second Amended and Restated Bylaws of the Company (the “Bylaws”), effective
immediately. The Bylaws Amendment amended Section 8 of ARTICLE III of the Bylaws to reduce the quorum requirement for all meetings
of stockholders of the Company from a majority of the voting power of the outstanding shares of stock entitled to vote to one-third of
the voting power of the outstanding shares of stock entitled to vote.
The foregoing description
of the Bylaws Amendment is qualified in its entirety by reference to the full text of the Bylaws Amendment, a copy of which is filed with
this Current Report on Form 8-K as Exhibit 3.1.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NeuroBo Pharmaceuticals, Inc. |
|
|
|
|
Date: November 4, 2022 |
By: |
/s/ Gil Price, M.D. |
|
|
Gil Price, M.D. |
|
|
President and Chief Executive Officer |
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Apr 2023 to Apr 2024